NCT00385580View on ClinicalTrials.gov

Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

October 31, 2010

Conditions
Prostate Cancer
Interventions
DRUG

dasatinib

Tablets, Oral, 100 mg or 70 mg, twice daily, treatment may continue until disease progression

DRUG

dasatinib

Tablets, Oral, 100 mg, once daily (QD) treatment may continue until disease progression

Trial Locations (11)

10021

Memorial Sloan-Kettering Cancer Center-Sidney Kimmel Center, New York

19111

Fox Chase Cancer Center, Philadelphia

21231

The Bunting Blaustein Cancer Research Building, Baltimore

34298

Local Institution, Montpellier

53792

University Of Wisconsin Paul P Carbone Comprehensive Ca Ctr, Madison

60637

University Of Chicago, Chicago

75015

Local Institution, Paris

90048

Cedars Sinai Medical Center, Los Angeles

94800

Local Institution, Villejuif

98109

Seattle Cancer Care Alliance, Seattle

00152

Local Institution, Rome

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT00385580 - Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer | Biotech Hunter | Biotech Hunter